Scholarlink

<p>Hyperuricemia (HUA) is a globally prevalent metabolic disorder that demands safe and efficacious uric acid-lowering agents. This study subjected <i>Lactiplantibacillus plantarum</i> Ta6, isolated from traditional Xinjiang fermented foods, to atmospheric pressure room temperature plasma (ARTP) mutagenesis, yielding a genetically stable mutant strain A2. Phenotypically, A2 displayed a 16.29% increase in uric acid degradation and achieved complete degradation of 100&#xa0;µg/mL inosine and guanosine. Its in vitro xanthine oxidase (XOD) inhibition rate reached 86.89%, which was comparable to that of allopurinol (87.88%) and significantly higher than the wild-type Ta6 (74.31%) (<i>p</i> &lt; 0.05). Transcriptomic analysis identified 1,210 differentially expressed genes (DEGs). Upregulation of salvage-pathway genes Phosphoribosyl Pyrophosphate Synthetase (PRPS) and Hypoxanthine-Guanine Phosphoribosyl Transferase (HGPRT) and downregulation of adenine deaminase suggested a potential shift in purine metabolic flux and altered intracellular purine interconversion. Furthermore, coordinated upregulation of all 24 genes in the peptidoglycan biosynthesis pathway indicated active cell wall remodeling. These findings identify a promising candidate probiotic strain and elucidate the molecular basis for ARTP-enhanced uric acid-lowering.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breeding of Highly Efficient Uric Acid-Lowering Lactic Acid Bacteria by ARTP Mutation and its Transcriptomic Analysis

  • 期刊论文

  • 发表日期：

    2026年7月8日

查看全文
  • Guanwen Ding,
  • Shengting Guo,
  • Jiarui Yu,
  • Yanxia Liang,
  • Qiyong Tang,
  • Jun Zeng,
  • Zhidong Zhang

摘要

Hyperuricemia (HUA) is a globally prevalent metabolic disorder that demands safe and efficacious uric acid-lowering agents. This study subjected Lactiplantibacillus plantarum Ta6, isolated from traditional Xinjiang fermented foods, to atmospheric pressure room temperature plasma (ARTP) mutagenesis, yielding a genetically stable mutant strain A2. Phenotypically, A2 displayed a 16.29% increase in uric acid degradation and achieved complete degradation of 100 µg/mL inosine and guanosine. Its in vitro xanthine oxidase (XOD) inhibition rate reached 86.89%, which was comparable to that of allopurinol (87.88%) and significantly higher than the wild-type Ta6 (74.31%) (p < 0.05). Transcriptomic analysis identified 1,210 differentially expressed genes (DEGs). Upregulation of salvage-pathway genes Phosphoribosyl Pyrophosphate Synthetase (PRPS) and Hypoxanthine-Guanine Phosphoribosyl Transferase (HGPRT) and downregulation of adenine deaminase suggested a potential shift in purine metabolic flux and altered intracellular purine interconversion. Furthermore, coordinated upregulation of all 24 genes in the peptidoglycan biosynthesis pathway indicated active cell wall remodeling. These findings identify a promising candidate probiotic strain and elucidate the molecular basis for ARTP-enhanced uric acid-lowering.